Heart and blood vessel health in cystic fibrosis
Part of Digestive system, Genetic & congenital, Heart & circulation, Lungs & breathing clinical trials.
This study looks at how cystic fibrosis affects the heart and blood vessels in people taking CFTR modulators (like Trikafta). It also compares results to healthy adults to understand if the medicine helps protect the heart.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of cystic fibrosis (diagnosed by sweat test or genetic testing).
- You must be 18 years or older.
- You must be taking a CFTR modulator medicine (e.g., Trikafta) for at least 3 months.
- You must be feeling well and stable, with no recent lung flare-ups or hospital stays in the past 4 weeks.
- You cannot be on long-term steroids or certain heart medications.
- You cannot be a smoker or have smoked in the last 10 years, and you cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a remote exercise program can help people with cystic fibrosis become more active and improve their heart health. You would exercise from home with guidance from a research team.
This study looks at how long-term diabetes affects people with cystic fibrosis. It helps researchers understand complications and improve care.
This study tests whether people with cystic fibrosis who are already on a triple combination CFTR modulator can stay on their treatment without interruptions or problems. It aims to make sure everyone gets the best, most consistent treatment for their CF.
This study measures how often people with cystic fibrosis who take elexacaftor-tezacaftor-ivacaftor (ETI) experience breathing limitations during exercise and what factors are linked to this.
This trial compares physical abilities between children with cystic fibrosis and healthy children. It aims to find differences that could lead to better care and therapies.
This study uses advanced diagnostic tests to help people whose cystic fibrosis (CF) diagnosis is unclear. It aims to give a clearer answer about whether you have CF or a related condition.
Hear when a new Cardiovascular (CV) Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.